Xencor, Inc Increase (Decrease) in Income Taxes Payable
Xencor, Inc (XNCR) reported Increase (Decrease) in Income Taxes Payable of $3.59 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2026-02-25
- Xencor, Inc increase (decrease) in income taxes payable for the quarter ending 2024-12-31 was $1.42M, a 89.62% decline year-over-year.
- Xencor, Inc increase (decrease) in income taxes payable for the quarter ending 2024-09-30 was $0.00.
- Xencor, Inc increase (decrease) in income taxes payable for the quarter ending 2023-12-31 was $13.63M.
- Xencor, Inc increase (decrease) in income taxes payable for the quarter ending 2023-09-30 was $0.00.
- Xencor, Inc increase (decrease) in income taxes payable for fiscal 2025 was $3.59M.
- Xencor, Inc increase (decrease) in income taxes payable for fiscal 2024 was -$4.48M, a 132.89% decline from fiscal 2023.
- Xencor, Inc increase (decrease) in income taxes payable for fiscal 2023 was $13.63M.
- Xencor, Inc increase (decrease) in income taxes payable for fiscal 2018 was -$157.00K, a 272.53% decline from fiscal 2017.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 6 month as first filed | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 9 month as first filed | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $3.59M 10-K · filed 2026-02-25 | |||||
| 2024-12-31 | $1.42M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-25 | $1.42M derived: sum of 2 quarters · filed 2026-02-25 | -$4.48M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2025-02-24 | -$5.90M 10-Q/A · filed 2025-02-24 | -$5.78M 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | -$5.90M 10-Q/A · filed 2025-02-24 | -$5.78M 10-Q · filed 2024-08-05 | ||||
| 2023-12-31 | $13.63M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-25 | $13.63M derived: sum of 2 quarters · filed 2026-02-25 | $13.63M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2025-02-24 | $0.00 10-Q/A · filed 2025-02-24 | ||||
| 2023-06-30 | $0.00 10-Q/A · filed 2025-02-24 | |||||
| 2022-09-30 | $388.00K 10-Q · filed 2023-11-08 | |||||
| 2020-09-30 | $804.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $895.00K 10-Q · filed 2021-11-08 | ||||
| 2020-06-30 | $91.00K 10-Q · filed 2021-08-04 | |||||
| 2019-09-30 | -$400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $304.00K derived: sum of 2 quarters · filed 2020-11-06 | $1.20M 10-Q · filed 2020-11-06 | $1.20M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2019-06-30 | $704.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.60M 10-Q · filed 2020-08-05 | $1.60M derived: sum of 3 quarters · filed 2021-02-24 | $1.60M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2019-03-31 | $900.00K 10-Q · filed 2020-05-08 | $899.00K derived: sum of 2 quarters · filed 2021-02-24 | $900.00K derived: sum of 3 quarters · filed 2021-02-24 | $900.00K derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2018-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $0.00 derived: sum of 2 quarters · filed 2021-02-24 | $0.00 derived: sum of 3 quarters · filed 2021-02-24 | -$157.00K 10-K · filed 2021-02-24 | ||
| 2018-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $1.00K derived: sum of 2 quarters · filed 2019-11-05 | -$156.00K 10-Q · filed 2019-11-05 | $0.00 derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$157.00K 10-Q · filed 2019-08-07 | -$1.00K derived: sum of 3 quarters · filed 2020-02-25 | -$456.00K derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-03-31 | -$157.00K 10-Q · filed 2019-05-09 | -$1.00K derived: sum of 2 quarters · filed 2020-02-25 | -$456.00K derived: sum of 3 quarters · filed 2020-02-25 | -$176.00K derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2017-12-31 | $156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$299.00K derived: sum of 2 quarters · filed 2020-02-25 | -$19.00K derived: sum of 3 quarters · filed 2020-02-25 | $91.00K 10-K · filed 2020-02-25 | ||
| 2017-09-30 | -$455.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$175.00K derived: sum of 2 quarters · filed 2018-11-05 | -$65.00K 10-Q · filed 2018-11-05 | -$400.00K derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-06-30 | $280.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $390.00K 10-Q · filed 2018-08-07 | $55.00K derived: sum of 3 quarters · filed 2019-02-26 | -$1.33M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-03-31 | $110.00K 10-Q · filed 2018-05-07 | -$225.00K derived: sum of 2 quarters · filed 2019-02-26 | -$1.61M derived: sum of 3 quarters · filed 2019-02-26 | |||
| 2016-12-31 | -$335.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$1.72M derived: sum of 2 quarters · filed 2019-02-26 | $65.00K 10-K · filed 2019-02-26 | |||
| 2016-09-30 | -$1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $400.00K 10-Q · filed 2017-11-08 | ||||
| 2016-06-30 | $1.78M 10-Q · filed 2017-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |